Who owns Verrica Pharmaceuticals Inc?
- Ticker: VRCA
- CUSIP Number: 92511w207
Tip: Access positions for across all investors
Analyze quarterly positions in Verrica Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Verrica Pharmaceuticals stock
Who bought or sold Verrica Pharmaceuticals Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Caligan Partners | 924k | $7.7M | 0% | Dec 2025 |
|
| Affinity Asset Advisors | 707k | $5.9M | 100% | Dec 2025 |
|
| Cannell Capital | 685k | $3.6M | 100% | Mar 2026 |
|
| Armistice Capital | 518k | $2.7M | -19% | Mar 2026 |
|
| Velan Capital Investment Management | 472k | $3.9M | 100% | Dec 2025 |
|
| Stonepine Capital Management | 354k | $2.9M | 100% | Dec 2025 |
|
| Boothbay Fund Management | 281k | $1.5M | 0% | Mar 2026 |
|
| Vanguard Capital Management | 189k | $999k | 100% | Mar 2026 |
|
| DAFNA Capital Management | 154k | $813k | -11% | Mar 2026 |
|
| Geode Capital Management | 139k | $735k | 105% | Mar 2026 |
|
| Vanguard Group | 138k | $1.1M | -39% | Dec 2025 |
|
| Marshall Wace | 85k | $708k | 100% | Dec 2025 |
|
| Squarepoint Ops | 75k | $398k | 126% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 65k | $344k | 100% | Mar 2026 |
|
| Two Sigma Investments | 51k | $268k | -57% | Mar 2026 |
|
| Jane Street | 49k | $260k | -52% | Mar 2026 |
|
| BlackRock | 39k | $204k | 578% | Mar 2026 |
|
| Renaissance Technologies | 26k | $219k | -10% | Dec 2025 |
|
| Mariner Wealth Advisors | 25k | $130k | 0% | Mar 2026 |
|
| State Street Corporation | 24k | $195k | 14% | Dec 2025 |
|
| Morgan Stanley | 22k | $118k | 2% | Mar 2026 |
|
| Northern Trust | 20k | $166k | 0% | Dec 2025 |
|
| Legacy Trust | 17k | $91k | 0% | Mar 2026 |
|
| XTX Topco | 15k | $122k | 100% | Dec 2025 |
|
| Bridgeway Capital Management | 12k | $100k | 0% | Dec 2025 |
|
| Beck Mack & Oliver | 12k | $64k | 0% | Mar 2026 |
|
| Quadrature Capital | 12k | $99k | 100% | Dec 2025 |
|
| UBS Group | 4.3k | $23k | 17692% | Mar 2026 |
|
| Tower Research Capital | 3.3k | $28k | 117% | Dec 2025 |
|
| Capital Analysts | 1.5k | $8.0k | 0% | Mar 2026 |
|
| Royal Bank of Canada | 965.00 | $5.1k | -20% | Mar 2026 |
|
| Vanguard Global Advisers | 862.00 | $4.6k | 100% | Mar 2026 |
|
| Salomon & Ludwin | 290.00 | $1.6k | 0% | Mar 2026 |
|
| New England Capital Financial Advisors | 200.00 | $1.1k | 0% | Mar 2026 |
|
| International Assets Investment Management | 175.00 | $960.995000 | 0% | Mar 2026 |
|
| Fortitude Family Office | 127.00 | $671.995100 | -79% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 110.00 | $581.999000 | 0% | Mar 2026 |
|
| Pnc Financial Services | 102.00 | $539.855400 | 0% | Mar 2026 |
|
| Optiver Holding B.V. | 31.00 | $163.999300 | 0% | Mar 2026 |
|
| MAI Wealth Advisors | 2.00 | $11.000000 | 0% | Mar 2026 |
|
| Barclays | 1.00 | $8.000000 | 0% | Dec 2025 |
|
Who sold out of Verrica Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Two Sigma Advisers | Dec 2025 | 44k | $369k |
| Sovran Advisors | Dec 2025 | 33k | $249k |
| Millennium Management | Dec 2025 | 23k | $192k |
| OMERS Administration Corporation | Dec 2025 | 23k | $188k |
| Goldman Sachs Group | Dec 2025 | 19k | $155k |
| Hrt Financial | Dec 2025 | 17k | $144k |
| Walleye Trading Advisors | Dec 2025 | 15k | $127k |
| Man Group | Dec 2025 | 11k | $94k |
| FMR | Sep 2025 | 3.3k | $14k |
| Covestor | Dec 2025 | 54.00 | $0 |
| CWM | Sep 2025 | 28.00 | $0 |
| Group One Trading | Dec 2025 | 3.00 | $24.999900 |